Ireland HSE delays Mounjaro reimbursement decision pending cost and clinical review

Ireland's HSE Drugs Group has met to consider adding Mounjaro (tirzepatide) to state reimbursement schemes but expects further meetings before deciding. The delay reflects ongoing assessment of cost-effectiveness and clinical evidence, leaving patients waiting for access. This is a routine administrative process with no immediate market impact.